Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
grade C 15.85 0.57% 0.09
KURA closed up 0.57 percent on Friday, January 18, 2019, on approximately normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical KURA trend table...

Date Alert Name Type % Chg
Jan 18 200 DMA Resistance Bearish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Doji - Bullish? Reversal 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.57%
Jan 17 Slingshot Bullish Bullish Swing Setup 0.57%
Jan 17 Wide Bands Range Expansion 0.57%
Jan 17 Overbought Stochastic Strength 0.57%

Older signals for KURA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.
Is KURA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.025
52 Week Low 10.2
Average Volume 244,547
200-Day Moving Average 16.3976
50-Day Moving Average 13.6126
20-Day Moving Average 15.008
10-Day Moving Average 16.327
Average True Range 0.8732
ADX 26.36
+DI 24.573
-DI 12.2116
Chandelier Exit (Long, 3 ATRs ) 14.4804
Chandelier Exit (Short, 3 ATRs ) 14.9196
Upper Bollinger Band 17.9095
Lower Bollinger Band 12.1065
Percent B (%b) 0.65
BandWidth 38.666045
MACD Line 0.7845
MACD Signal Line 0.7778
MACD Histogram 0.0067
Fundamentals Value
Market Cap 316.81 Million
Num Shares 20 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -10.36
Price-to-Sales 0.00
Price-to-Book 6.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.56
Resistance 3 (R3) 17.66 17.18 17.28
Resistance 2 (R2) 17.18 16.75 17.14 17.18
Resistance 1 (R1) 16.52 16.48 16.85 16.42 17.08
Pivot Point 16.04 16.04 16.21 16.00 16.04
Support 1 (S1) 15.38 15.61 15.71 15.28 14.62
Support 2 (S2) 14.90 15.34 14.86 14.52
Support 3 (S3) 14.24 14.90 14.43
Support 4 (S4) 14.14